Q1 Earnings Estimate for EWTX Issued By HC Wainwright

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Edgewise Therapeutics in a note issued to investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.43) per share for the quarter. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.60) EPS.

A number of other equities research analysts also recently issued reports on EWTX. Piper Sandler reiterated an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. Wedbush cut their price target on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada boosted their price objective on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Stifel Nicolaus set a $25.00 target price on Edgewise Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.36.

Edgewise Therapeutics Stock Performance

Shares of NASDAQ EWTX opened at $29.66 on Friday. The stock has a market capitalization of $3.14 billion, a P/E ratio of -18.77 and a beta of 0.27. The stock’s fifty day moving average is $27.53 and its 200 day moving average is $21.05. Edgewise Therapeutics has a 52 week low of $10.60 and a 52 week high of $31.82.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04).

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Edgewise Therapeutics by 6.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock valued at $963,000 after acquiring an additional 2,463 shares in the last quarter. Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics in the first quarter valued at about $47,000. Goldman Sachs Group Inc. raised its position in Edgewise Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company’s stock valued at $8,066,000 after purchasing an additional 19,753 shares during the last quarter. Strs Ohio acquired a new stake in shares of Edgewise Therapeutics during the first quarter valued at about $84,000. Finally, AlphaQuest LLC grew its holdings in shares of Edgewise Therapeutics by 128.6% during the second quarter. AlphaQuest LLC now owns 21,390 shares of the company’s stock worth $280,000 after purchasing an additional 12,032 shares during the last quarter.

Insider Transactions at Edgewise Therapeutics

In related news, Director Badreddin Edris sold 115,471 shares of the stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total value of $3,399,466.24. Following the completion of the transaction, the director owned 19,820 shares of the company’s stock, valued at $583,500.80. This represents a 85.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 23.20% of the stock is currently owned by corporate insiders.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.